
The Time Is Now for Women and Girls in STEM
Women's health continues to be at risk.
This is not news. Women have been excluded and underrepresented in the research and decision-making that shape health care. Their voices, ideas, and leadership are not only overdue, but they are also essential to closing the gaps that continue to put women's lives at risk.
Women's health receives less funding for research and treatment than men—at a staggering rate. According to the World Economic Forum, only 1 percent of funding for innovation and research outside of oncology in 2020 went to female-specific conditions. Our concerns are often dismissed by physicians or considered taboo to discuss socially. In a 2022 Kaiser Family Fund Women's Health Survey, 29 percent of women who had seen a health care provider in the prior two years said their doctor had dismissed their concerns, 15 percent said their provider did not believe them, and 13 percent said their provider had suggested they were personally to blame.
Photograph of Dr. Karidia Diallo working in a laboratory with an ABI DNA Analyzer machine wearing protective gear, placing samples of DNA with HIV from PEPFAR (countries from the President's Emergency Plan for AIDS Relief)...
Photograph of Dr. Karidia Diallo working in a laboratory with an ABI DNA Analyzer machine wearing protective gear, placing samples of DNA with HIV from PEPFAR (countries from the President's Emergency Plan for AIDS Relief) persons, in order to test their resistance to medications, in 2007. More
Smith Collection/Gado/Getty Images
But it doesn't have to be that way. Increasingly, women are taking a stand, breaking down societal norms that have been in place for decades and approaching health and wellness in a holistic way. Here's how you can help.
Get Loud About the Things That Have Previously Made People Uncomfortable.
Women spend more than a third of their lives in some state of menopause (peri- or post-) with symptoms ranging from sleep issues and mood changes to hot flashes and weight gain, and yet only a fraction seek treatment. According to the Mayo Clinic, this lack of treatment (stemming from lack of research and awareness), has serious economic implications; the U.S. economy loses approximately $1.8 billion annually due to lost work time related to menopausal symptoms, with total costs, including medical expenses, reaching $26.6 billion.
The same is true for women during childbearing years. One in four pregnancies end in miscarriage, and 1 in 8 women will need fertility treatment at some point in their lives; yet the topics are rarely discussed.
But the tide is changing, and both issues are reaching mainstream conversation due in part to celebrities willing to share their own personal experiences (think: Naomi Watts and her recently released book, or Meghan Markle and her op-ed penned for The New York Times), and companies like Alloy, Joylux, and Maven Clinic.
Examine Longevity From a 360 Perspective.
We all want to live longer, better—and it's time for us to expand our perceptions of what that means. Longevity is no longer just about annual checkups, treating illness, eating well, exercising, and sleeping enough. It now includes a more holistic view of health. This shift is especially relevant for women who have longer life expectancies than men, and who are—according to research—more open to holistic and alternative treatments.
Research continues to show that well-being and self-perception are just as critical to longevity as other factors. Merz Aesthetics' recently released, Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation, reinforces this connection, revealing 74 percent of respondents say confidence is essential to overall well-being. The first-of-its-kind study surveyed 15,000 adults from around the world to establish an industry-first connection between our outward appearance, inner self-concept, and overall well-being. The company is also spearheading regenerative aesthetics in a unique and holistic way by investing in products and devices that work with the body's own capabilities to restore, maintain, and enhance skin health at a cellular level.
Other areas of focus are neuroplasticity leading to focus in neurotechnology as we look toward brain health and cognitive enhancement, joint treatments through regenerative technologies like platelet rich plasma therapy, and the overarching concept of biohacking. Living longer with a better quality of life is the ultimate—and attainable—goal.
Empower More Women in STEM (Science, Technology, Engineering, and Mathematics).
It should go without saying that if we want change, we need to start from within.
While we have made progress on the issue—with women now making up half of all medical school students—we still have a long way to go. Women make up only one-third of all practicing physicians, and the pay gap is staggering, with women earning an estimated $2 million less than their male counterparts over a 40-year career. When you consider the statistic that the prognosis for patients seeing a female doctor is far better than those who see male doctor, with both a lower mortality and chance of hospital readmission—it's shocking we haven't already implemented these changes.
Support organizations like the American Medical Women's Association or Women in Medicine, advocate for pay transparency, reach out to your policymakers demanding change, and encourage the girls in your life with interest in STEM to pursue careers in the field.
We need them now more than ever.
Terri L. Phillips, MD, FAAP, has been chief medical affairs officer at Merz Aesthetics for over five years.
The views expressed in this article are the writer's own.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


The Hill
12 hours ago
- The Hill
Obamacare preventive care mandate wins in Supreme Court ruling
The Big Story The Supreme Court on Friday upheld a key Affordable Care Act requirement that insurance companies cover certain preventative measures recommended by an expert panel. © AP Justices upheld the constitutionality of the provision in a 6-3 decision and protected access to preventative care for about 150 million Americans. The justices found that the secretary of the Department of Health and Human Services has the power to appoint and fire members of the U.S. Preventative Services Task Force (USPSTF). The cases started when a small business in Texas and some individuals filed a lawsuit against the panel's recommendation that pre-exposure prophylaxis (PreP) for HIV be included as a preventative care service. They argued that covering PreP went against their religious beliefs and would 'encourage homosexual behavior, intravenous drug use, and sexual activity outside of marriage between one man and one woman.' The plaintiffs further argued that the USPSTF mandates are unconstitutional because panel members are 'inferior officers' who are not appointed by the president or confirmed by the Senate. While the panel is independent, they said that since their decisions impact millions of people members should be confirmed. A U.S. district judge in 2023 ruled that all preventative-care coverage imposed since the ACA was signed into law are invalid and a federal appeals court judge ruled in agreement last year. The Biden administration appealed the rulings to the Supreme Court, and the Trump administration chose to defend the law despite its long history of disparaging Obamacare. Though public health groups celebrated the ruling Friday, some noted another potential outcome. 'While this is a foundational victory for patients, patients have reason to be concerned that the decision reaffirms the ability of the HHS secretary, including our current one, to control the membership and recommendations of the US Preventive Services Task Force that determines which preventive services are covered,' Anthony Wright, executive director of Families USA, said in a statement. 'We must be vigilant to ensure Secretary Kennedy does not undo coverage of preventive services by taking actions such as his recent firing of qualified health experts from the CDC's independent vaccine advisory committee and replacing them with his personal allies.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: New Hampshire lawmakers give final approval to gender-affirming care ban New Hampshire lawmakers on Thursday gave final approval to bills that would ban gender-affirming care for transgender minors in the state, sending the measures to Republican Gov. Kelly Ayotte, who has not yet said whether she will sign them. State lawmakers voted to pass House Bill 377, which would prohibit doctors from administering puberty blockers and hormones to transgender youth beginning next year. The measure includes … FDA expanding COVID vaccine warnings over rare heart side effect The U.S. Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include information on two rare heart side effects. Myocarditis, or inflammation of the heart muscle, and pericarditis, or inflammation of the thin sac surrounding the heart — are two conditions that a small number of people have experienced after receiving the mRNA COVID-19 shot. The rare cases of myocarditis … What causes a stroke? Learn the triggers and risk factors Most Americans likely know at least a little about the signs of a stroke. While early intervention is vital for a positive outcome, medical experts also stress the need to prevent strokes, which the Stroke Foundation reports are the fifth leading cause of death in the U.S. The key to prevention is knowing what causes these brain attacks. According to the American Heart Association, a stroke occurs when a blood vessel to the … In Other News Branch out with a different read from The Hill: GOP leader sets Saturday vote on Trump 'big, beautiful bill' despite Republican pushback Senate Majority Leader John Thune (R-S.D.) told Senate Republicans to expect to see the legislative text of the budget reconciliation package on Friday evening and then to vote at noon Saturday to begin debate on President Trump's tax and spending bill. Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: GOP leader sets Saturday vote on Trump 'big, beautiful bill' despite Republican pushback Senate Majority Leader John Thune (R-S.D.) told Senate Republicans to expect to see the legislative text of the budget reconciliation package on Friday … Read more 5 takeaways from the Supreme Court's birthright citizenship ruling The Supreme Court handed President Trump a clear victory Friday, stopping judges from issuing nationwide injunctions that block his executive order … Read more What People Think Opinions related to health submitted to The Hill: Thank you for signing up! Subscribe to more newsletters here